Arterial gipertoniya bilan og‘rigan qandli diabet 2-turi bemorlarda qon-tomir asoratlari: xavf omillari va profilaktika
Annotatsiya
Qandli diabet 2 turi va arterial gipertoniya bilan og‘rigan bemorlarda qon-tomir asoratlari tibbiyotda muhim muammo hisoblanadi. Maqolada ushbu komorbid holatlarning patogenezi, klinik jihatlari va asoratlari muhokama qilinadi. Qandli diabet va arterial gipertoniyaning birgalikda kechishi mikro va makroqon-tomir asoratlarining jadal rivojlanishiga olib keladi. Qon bosimining uzoq muddatli oshishi diabetogen ta’sir ko‘rsatib, yurak-qon tomir xavfini kuchaytiradi. Asosiy xususiyatlar—tuzga sezuvchanlik, albuminuriya, izolirlangan sistolik gipertoniya va ortostatik gipotoniya—asoratlarni yanada kuchaytiradi. Mualliflar asoratlarni oldini olish va davolash borasidagi eng so‘nggi tadqiqot natijalarini ko‘rib chiqib, qon bosimini maqsadli darajada saqlash va individual terapiya ahamiyatini ta’kidlaydilar. Shuningdek, metabolik nazorat va hayot tarzini o‘zgartirish orqali asoratlarni oldini olish imkoniyati yoritilgan. Xulosa qilib, qandli diabet va arterial gipertoniyada asoratlarni oldini olish uchun tizimli va kompleks yondashuv talab etiladi.
Mualliflar haqida
Adabiyotlar ro'yxati
Updated European Guidelines for the Management of Cardiovascular Diseases in Diabetes Mellitus (2023): Perspective of Russian Experts, Published by the Cardiology Development Support Foundation, Volume 11, Issue 40, December 2023, International Heart and Vascular Disease Journal. [in Russian].
Nelson A.J., Peterson E.D., Pagidipati N.J., Atherosclerotic cardiovascular disease and heart failure: determinants of risk and outcomes in patients with diabetes. Progr Cardiovasc Dis. 2019;62:306–314. DOI:10.1016/j.pcad.2019.07.00
Roth G.A., Mensah G.A., Johnson C.O., Addolorato G., Ammirati E., Baddour L.M., GBD-NHLBI- JACC Global Burden of Cardiovascular Diseases Writing Group. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update from the GBD 2019 Study. J. Am. Coll. Cardiol. 2020;76(25):2982–3021. DOI: 10.1016/j. jacc.2020.11.010.
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: A pooled analysis of 1479 population-based measurement studies with 19•1 million participants. Lancet. 2017;389(10064):37–55. DOI: 10.1016/S0140-6736(16)31919-5.
Emdin C.A., Anderson S.G., Woodward M., Rahimi K., Usual Blood Pressure and Risk of New-Onset Diabetes: Evidence from 4.1 Million Adults and a Meta-Analysis of Prospective Studies. J. Am. Coll. Cardiol. 2015;66(14):1552–1562. DOI: 10.1016/j.jacc.2015.07.059.
Holtrop J., Spiering W., Nathoe H.M., De Borst G.J., Kappelle L.J., De Valk H.W., Apparent therapy- resistant hypertension as risk factor for the development of type 2 diabetes mellitus. J. Hypertens. 2020;38(1):45–51. DOI: 10.1097/HJH.0000000000002227.
Brands M.W. Role of insulin-mediated antinatriuresis in sodium homeostasis and hypertension. Hypertension. 2018;72(6):1255–1262. DOI: 10.1161/HYPERTENSIONAHA.118.11728.
Solini A., Zoppini G., Orsi E., Fondelli C., Trevisan R., Vedovato M., Resistant hypertension in patients with type 2 diabetes: Clinical correlates and association with complications. J. Hypertens. 2014;32(12):2401–2410. DOI: 10.1097/HJH.0000000000000350.
Wang Q., Ma W., Xia J., Li M., Fan Y., Impact of pulse pressure on left ventricular geometry and function in elderly type 2 diabetic patients. Chinese Journal of Medical Imaging Technology. 2018;34(1):43–46. DOI: 10.13929/j.1003-3289.201703102.
Prenner S.B., Chirinos J.A., Arterial stiffness in diabetes mellitus. Atherosclerosis. 2015;238(2):370–379. DOI: 10.1016/j.atherosclerosis.2014.12.023.
Abrignani M.G., Physical exercise and risk of arterial hypertension and diabetes mellitus. Let’s move, it is never too late. Eur J Prev Cardiol.2018; 25(10): 1063-1064. doi: 10.1177/2047487318781116.
Filimonova A.S., Rasova S.A., Sopenko I.V., Arterial Hypertension and Related Factors in Patients with Type 2 Diabetes Mellitus. Actual Scientific Research in the Modern World. 2021; No. 12-1(80): 143–148. [in Russian].
Smulyan H., Lieber A., Safar M.E. Hypertension, Diabetes Type II, and Their Association: Role of Arterial Stiffness. Am J Hypertens. 2016; 29(1): 5-13. doi: 10.1093/ajh/hpv107.
Rishko O.A., Derbak M.A., Ihnatko Y.Y., The clinical experience of the effective use of dapagliflozin in comorbid cardiac patients with concomitant type 2 diabetes mellitus and arterial hypertension on the background of overweight in outpatient setting. Wiad Lek. 2022; 75(10): 2397-2401. doi: 10.36740/WLek202210114.
Berra C., Manfrini R., Regazzoli D., Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists. Pharmacol Res. 2020; 160: 105052. doi: 10.1016/j.phrs.2020.105052.
Chahoud J., Mrad J., Semaan A., Prevalence of diabetes mellitus among patients with essential arterial hypertension. J Med Liban. 2015;63(2):74-80. doi: 10.12816/0012554.
Chernatska O., Demikhova N., Improvement of treatment in persons with arterial hypertension and type 2 diabetes mellitus. Georgian Med News. 2018; (284): 47-51.
Optimization of the Treatment of Hypertension in Patients with Diabetes Mellitus. System Analysis and Management in Biomedical Systems. 2020; Vol. 19, No. 4: 37–41. DOI: 10.36622/VSTU.2020.19.4.005.[in Russian]
Iadecola C., Gottesman R.F., Neurovascular and ognitive dysfunction in hypertension. Circ. Res. 2019;124(7):1025–1044. DOI: 10.1161/CIRCRESAHA.118.313260.
Steffen P.L.S., Mendonça C.S., Meyer E., Motivational Interviewing in the Management of Type 2 Diabetes Mellitus and Arterial Hypertension in Primary Health Care: An RCT. Am J Prev Med. 2021 May; 60(5): e203-e212. doi: 10.1016/j.amepre.2020.12.015.
ElSayed N.A., Aleppo G., Aroda V.R., Standards of Care in Diabetes—2023. Diabets Care. 2023; 46(S1): 1-291. doi: https://diabetesjournals.org/care/issue/46/Supplement_1
Draznin B., Aroda V.R., Bakris G., 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022 American Diabetes Association Professional Practice Committee. 2022; 45(Suppl 1): 144-174. doi: 10.2337/dc22-S010.
de Lira C.A.B., Viana R.B., Luz N.F., Analysis of type 2 diabetes mellitus and arterial hypertension content in exercise physiology textbooks. Adv Physiol Educ. 2019; 43(3): 253-258. doi: 10.1152/advan.00043.2019.
Comini L.O., de Oliveira L.C., Borges L.D., Prevalence of chronic kidney disease in Brazilians with arterial hypertension and/or diabetes mellitus. J Clin Hypertens (Greenwich). 2020 Sep; 22(9): 1666-1673. doi: 10.1111/jch.13980.
Huang D, Refaat M, Mohammedi K., Macrovascular Complications in Patients with Diabetes and Prediabetes. Biomed Res Int. 2017:7839101. doi:10.1155/2017/7839101.
Cui J, Liu Y, Li Y., Type 2 Diabetes and Myocardial Infarction: Recent Clinical Evidence and Perspective. Front Cardiovasc Med. 2021;8:644189. doi:10.3389/fcvm.2021.644189.
Nowbar AN, Gitto M, Howard JP, Mortality From Ischemic Heart Disease. Circ Cardiovasc Qual Outcomes. 2019;12(6):e005375. doi:10.1161/CIRCOUTCOMES.118.005375.
Jensen LO, Maeng M, Thayssen P, Influence of diabetes mellitus on clinical outcomes following primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2012;109(5):629-35. doi:10.1016/j.amjcard.2011.10.018.
Ceriello A., Hyperglycemia and the vessel wall: the pathophysiological aspects on the atherosclerotic burden in patients with diabetes. Eur J Cardiovasc Prev Rehabil. 2010 May;17(1):S15–9.
Duckworth W, Abraira C, Moritz T, VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129.
Istamova S.S., LEFT VENTRICULAR DIASTOLIC DYSFUNCTION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION IN COMORBID CONDITION //Euro-Asia Conferences. – 2021. – . 1. –
№. 1. – . 334-338
de Boer IH, et al. Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. Arch Intern Med. 2008 Sep 22;168(17):1867–73.
ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New Engl J Med. 2008;358:2560.
Tashkenbaeva E.N., Associated Risk Factors of Cardiovascular Events in Postmenopausal Women. Cardio. 2020; Vol. 1, No. 3. [in Russian].
Center for Disease Control of Prevention. SEARCH for Diabetes in Youth. [accessed November 13, 2010]. Available at: http://www.cdc.gov/diabetes/pubs/factsheets/search.htm#3.
Ceriello A, Ihnat MA, Thorpe JE. The ‘metabolic memory’: is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab. 2009;94:410–415.
Ayerden EF, et al. The relationship between vascular endothelial growth factor (VEGF) and microalbuminuria in patients with essential hypertension. Intern Med. 2008;47(17):1511–6.
Saran R., Robinson B., Abbott K.C., Agodoa L.Y.C., Bragg-Gresham J., Balkrishnan R., US Renal Data System 2018 Annual Data Report: Epidemiology of kidney disease in the United States. Am. J. Kidney Dis. 2019;73(3 Suppl 1):A7–A8. DOI: 10.1053/j.ajkd.2019.01.001
Viazzi F., Piscitelli P., Ceriello A., Fioretto P., Giorda C., Guida P., Resistant hypertension, time-updated blood pressure values and renal outcome in type 2 diabetes mellitus. J. Am. Heart Assoc. 2017;6:e006745. DOI: 10.1161/JAHA.117.006745.
Ushbu asar saytida mavjud litsenziyalar Creative Commons «Attribution» (««Atribut») 4.0 Butun dunyo bo'ylab.